Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Fineline Cube Jul 13, 2026
Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Fineline Cube Jul 13, 2026
Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Fineline Cube Jul 13, 2026
Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Fineline Cube Jul 13, 2026
Company Deals

Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies

Fineline Cube Apr 9, 2024

UK life sciences investment firm Medicxi has taken the lead in a $62 million Series...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA

Fineline Cube Apr 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...

Company Drug

Abbisko Therapeutics Achieves Milestone in Global Phase III Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Apr 9, 2024

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the completion of subject...

Company Drug

Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101

Fineline Cube Apr 9, 2024

Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...

Company Medical Device

Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China

Fineline Cube Apr 8, 2024

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...

Company Deals

Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates

Fineline Cube Apr 8, 2024

German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...

Company Deals

Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio

Fineline Cube Apr 8, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical...

Policy / Regulatory

China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus

Fineline Cube Apr 8, 2024

The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...

Company Drug

AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer

Fineline Cube Apr 8, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...

Company Drug

Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients

Fineline Cube Apr 8, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...

Policy / Regulatory R&D

Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development

Fineline Cube Apr 8, 2024

The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...

Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Company Drug

Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment

Fineline Cube Apr 8, 2024

The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...

Company

Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort

Fineline Cube Apr 8, 2024

Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 8, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...

Company Deals

Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China

Fineline Cube Apr 8, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...

Company Drug

Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024

Fineline Cube Apr 8, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base

Fineline Cube Apr 8, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space,...

Company Deals

Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation

Fineline Cube Apr 8, 2024

Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...

Posts pagination

1 … 405 406 407 … 693

Recent updates

  • Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer
  • Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
  • Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma
  • Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan
  • Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Company Drug

Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.